Cell-Free DNA Chromatin Immunoprecipitation (ChIP) for Diagnosing Cancer

Part of paid clinical trials in Orlando, Florida.

Sponsor
University of Central Florida
Study ID
NCT06148298
Status
Recruiting
Apply to this trial

Conditions

  • Cancer of Pancreas

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Non-Human Subject Research study. — OTHER
    This is a Non-Human Subject Research study. There is no intervention. All participants are de-identified.

Study Details

The goal of this research is to use chromatin immunoprecipitation, a method used to study protein-DNA interaction, as a tool to diagnose and prognose pancreatic ductal adenocarcinoma in human samples. This is a Non-Human Subject Research study. All participants are de-identified.

Key Dates

First listed
Nov 28, 2023
Start date
May 24, 2023
Status verified
Dec 2024
Primary completion
May 31, 2025
Completion
May 31, 2025

Study Design

Enrollment
24 participants (estimated)

Arms

  • Arm: Pancreatic Ductal Adenocarcinoma

Primary Outcome Measure

Level of c-ERBB1 in blood using Chromatin immunoprecipitation and Reverse transcription-quantitative polymerase chain reaction [ Time Frame: 1 year ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
University of Central FloridaOrlandoFlorida32816-

Find similar trials in Orlando, FL

By research site
University of Central Florida· Orlando, FL

Related Studies